EUCTR2005-003422-26-SE进行中（未招募）不适用
Immunological and virological effects of high dose intravenous immunoglobulin (IVIG) treatment added to antiretroviral therapy against HIV
Göteborg University0 个研究点目标入组 5 人开始时间: 2006年3月8日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.HIV-1 infected
- •2.Man or woman, =18 years old
- •3.Ability to understand and provide written informed consent
- •4.HIV-treatment with 2NRTI + PI/r =3 years
- •5.HIV-RNA <20 copies/mL =2.5 years.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Pregnancy
- •2.Women of childbearing potential not practicing birth control during the study.
- •3.History of antiretroviral treatment failure
- •4.Risk factors for tromboembolic disease, i.e. Age >70 years, hypertonia, diabetes mellitus, history of vascular disease or trombosis, platelet dysfunction disorders, immobilisation, severe hypovolemia or diseases with hyperviscosity.
- •5.Side effects on previous IVIG-treatment
研究者
相似试验
已完成
4 期
Immunogenicity and safety of high-dose versus double-dose quadrivalent inactivated influenza vaccine in adult kidney transplant recipients: A randomized control trialKidney transplant recipientsImmunogenicity, safety, immunocompromised, solid organ transplant recipientsTCTR20230510005Faculty of Medicine Ramathibodi Hospital, Mahidol University120
进行中（未招募）
不适用
Virological and immunological safety of a dose reduction strategy antiretroviral regimen with efavirenz / tenofovir / emtricitabineHIV -1 infectionMedDRA version: 14.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2012-004970-24-ESFundació Clinic per a la Recerca Biomèdica
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderEUCTR2019-000655-14-BESanofi Pasteur1,540
已完成
3 期
Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and OlderFlu10047438InfluenzaNL-OMON48124Sanofi-aventis340
进行中（未招募）
1 期
Study to Assess the Immuno Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in European Adults 60 Years and OlderPrevention of influenza infection in adults from 60 years of age and olderMedDRA version: 20.0Level: PTClassification code 10022000Term: InfluenzaSystem Organ Class: 10021881 - Infections and infestationsEUCTR2019-000655-14-DESanofi Pasteur1,540